Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

被引：0
|
作者：
Cho, B. C. [1 ]
Cheng, Y. [2 ]
Zhou, C. [3 ]
Ohe, Y. [4 ]
Imamura, F. [5 ]
Lin, M-C. [6 ]
Majem, M. [7 ]
Shah, R. [8 ]
Rukazenkov, Y. [9 ]
Todd, A. [10 ]
Markovets, A. [11 ]
Barrett, C. [11 ]
Chmielecki, J. [11 ]
Gray, J. E. [12 ]
Ramalingam, S. S. [13 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, Seoul, South Korea
[2] Jilin Prov Canc Hosp, Dept Oncol, Changchun, Jilin, Peoples R China
[3] Tongji Univ, Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan
[7] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[8] Maidstone & Tunbridge Wells NHS Trust, Maidstone Hosp, Kent Oncol Ctr, Maidstone, Kent, England
[9] AstraZeneca, GMED Oncol, Global Med Dev, Cambridge, England
[10] AstraZeneca, Biometr & Informat Sci, Cambridge, England
[11] AstraZeneca, IMED Biotech Unit, Translat Sci, Waltham, ME USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [41] Patients with uncommon EGFR mutations also benefit from first-line osimertinib
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (02) : 84 - 84
  • [42] Interpretation of Resistance Data from Randomized Trials of First-Line Antiretroviral Treatment
    Clotet, Bonaventura
    Hill, Andrew
    van Delft, Yvon
    Gupta, Ravindra Kumar
    Moecklinghoff, Christiane
    AIDS REVIEWS, 2012, 14 (04) : 247 - 255
  • [43] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [44] Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
    Assya Akli
    Nicolas Girard
    Vincent Fallet
    Gaelle Rousseau-Bussac
    Valérie Gounant
    Sylvie Friard
    Jean Trédaniel
    Cécile Dujon
    Marie Wislez
    Boris Duchemann
    Etienne Giroux-Leprieur
    Targeted Oncology, 2022, 17 : 675 - 682
  • [45] Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort
    Piotrowska, Zofia
    Chen, Lanyi Nora
    Shum, Elaine
    Park, Cathleen
    Guo, Matthew
    Liu, Ying
    Tran, Misha
    Marks, Jennifer Aline
    Banwait, Mandeep
    Liu, Stephen V.
    Scott, Susan Combs
    Bestvina, Christine M.
    Riess, Jonathan W.
    Marrone, Kristen A.
    Hall, Richard Delmar
    Gentzler, Ryan D.
    Shu, Catherine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
    Akli, Assya
    Girard, Nicolas
    Fallet, Vincent
    Rousseau-Bussac, Gaelle
    Gounant, Valerie
    Friard, Sylvie
    Tredaniel, Jean
    Dujon, Cecile
    Wislez, Marie
    Duchemann, Boris
    Giroux-Leprieur, Etienne
    TARGETED ONCOLOGY, 2022, 17 (06) : 675 - 682
  • [47] First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
    Cheng, Y.
    Yu, Y.
    Fan, Y.
    Jiang, L.
    Wu, L.
    Hu, J.
    Wang, J.
    Yao, W.
    Han, Z.
    Yao, Y.
    Fang, J.
    Sun, M.
    Wang, Q.
    Pan, Y.
    Wu, R.
    Liu, J.
    Liu, Y.
    Kulkarni, D.
    Huang, X.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1689
  • [48] ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
    Yu, H.
    Goldberg, S.
    Le, X.
    Piotrowska, Z.
    Smith, P.
    Mensi, I.
    Kirova, B.
    Chmielecki, J.
    Li-Sucholeicki, X.
    Szekeres, P.
    Doughton, G.
    Patel, G.
    Jewsbury, P.
    Riess, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S647 - S647
  • [49] A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
    Viray, Hollis
    Piper-Vallillo, Andrew J.
    Widick, Page
    Academia, Emmeline
    Shea, Meghan
    Rangachari, Deepa
    VanderLaan, Paul A.
    Kobayashi, Susumu S.
    Costa, Daniel B.
    CANCERS, 2024, 16 (06)
  • [50] A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration
    Mimura, C.
    Tachihara, M.
    Kaneshiro, K.
    Kono, Y.
    Fujimoto, S.
    Hatakeyama, Y.
    Dokuni, R.
    Iwamoto, N.
    Matsumura, K.
    Kobayashi, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1071 - S1072
12345